BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

doi:10.1186/1757-2215-2-14

Journal of Ovarian Research

Volume 2

Viewing options:

Abstract
Full text
PDF (2.4MB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on PubMed Central
Other articles by authors
on Google Scholar

Tagliaferri P
Ventura M
Baudi F
Cucinotto I
Arbitrio M
Di Martino MT
Tassone P

on PubMed

Tagliaferri P
Ventura M
Baudi F
Cucinotto I
Arbitrio M
Di Martino MT
Tassone P
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Review

BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?

Pierosandro Tagliaferri¹^,2 , Monica Ventura¹^,2 , Francesco Baudi¹^,2 , Iole Cucinotto¹^,2 , Mariamena Arbitrio¹^,2 , Maria Teresa Di Martino¹^,2 and Pierfrancesco Tassone¹^,2

¹Medical Oncology Unit and Center for Genetic Counseling and Innovative Treatments, Tommaso Campanella Cancer Center,Catanzaro 88100, Italy

²Magna Græcia University Campus Salvatore Venuta, Catanzaro 88100, Italy

author email corresponding author email

Journal of Ovarian Research 2009, 2:14doi:10.1186/1757-2215-2-14


Published:	13 October 2009

Abstract

Ovarian epithelial tumors are an hallmark of hereditary cancer syndromes which are related to the germ-line inheritance of cancer predisposing mutations in BRCA1 and BRCA2 genes. Although these genes have been associated with multiple different physiologic functions, they share an important role in DNA repair mechanisms and therefore in the whole genomic integrity control. These findings have risen a variety of issues in terms of treatment and prevention of breast and ovarian tumors arising in this context. Enhanced sensitivity to platinum-based anticancer drugs has been related to BRCA1/2 functional loss. Retrospective studies disclosed differential chemosensitivity profiles of BRCA1/2-related as compared to "sporadic" ovarian cancer and led to the identification of a "BRCA-ness" phenotype of ovarian cancer, which includes inherited BRCA1/2 germ-line mutations, a serous high grade histology highly sensitive to platinum derivatives. Molecularly-based tailored treatments of human tumors are an emerging issue in the "era" of molecular targeted drugs and molecular profiling technologies. We will critically discuss if the genetic background of ovarian cancer can indeed represent a determinant issue for decision making in the treatment selection and how the provocative preclinical findings might be translated in the therapeutic scenario. The presently available preclinical and clinical evidence clearly indicates that genetic background has an emerging role in treatment individualization for ovarian cancer patients.